Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Jacquemin B, Schikowski T, Carsin AE, Hansell A, Kramer U, Sunyer J, Probst-Hensch N, Kauffmann F, Kunzli N. The role of air pollution in adult-onset asthma: a review of the current evidence. Semin Resp Crit Care. 2012 Dec;33(6):606-19. doi: 10.1055/s-0032-1325191
Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012 Jan 1;64(1):54-67.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Hershey N, Cann CI, Rothman KJ. Reply: overcoming hurdles to epidemiologic research. E & HR. 1985 Mar;7(2):9. doi: 10.2307/3564146
Cann CI, Rothman KJ. IRBs and epidemiologic research: how inappropriate restrictions hamper studies. E & HR. 1984 Jul;6(4):5-7. doi: 10.2307/3564590